Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Weitere Synonyme anzeigen
Wählen Sie die gewünschte Spezies
The CD82 is a functional surface marker of long-term repopulating hematopoietic stem cells (LT-HSCs) that maintains quiescence through interaction with DARC (zeige DARC Proteine)-expressing macrophages in the bone marrow stem cell niche.
The perturbation of CD82-ganglioside-CD44 (zeige CD44 Proteine) signaling attenuates pathological angiogenesis.
Loss of Kai1 expression is associated with neoplasm metastasis.
The synergistic effects of CD82 and GM3 (zeige GRM6 Proteine) or GM2 (zeige CYB5D2 Proteine)/GM3 (zeige GRM6 Proteine) ganglioside on EGFR (zeige EGFR Proteine) expression and phosphorylation and cMet activation are responsible for CD82 inhibition of EGF (zeige EGF Proteine)- and HGF (zeige HGF Proteine)-dependent cell motility and migration of Hepa1-6 cells.
CD81 (zeige CD81 Proteine) promotes the microvillus formation and/or extension while tetraspanin CD82 inhibits these events. In addition, CD81 (zeige CD81 Proteine) enhances the outward bending of the plasma membrane while CD82 inhibits it.
the CD82 tetraspanin is specifically recruited to pathogen-containing phagosomes prior to fusion with lysosomes.
KAI1 has a role in promotion of cell proliferation and mammary gland hyperplasia by the gp78 ubiquitin ligase
Hypoxia-dependent induction of KAI1 was directly mediated by hypoxia-inducible factor-1alpha binding on the promoter, which subsequently caused increased recruitment of RNA polymerase II for transcriptional activation.
An antibody to this protein that can specifically detect murine Kai1/CD82, should be useful in addressing the mechanism of action of Kai1 in metastatic suppression.
gp78 (zeige AMFR Proteine) promotes sarcoma metastasis by targeting KAI1 for degradation
CD82 is a component of the promiscuous TIMP-1 (zeige TIMP1 Proteine) interacting protein complex on cell surface of human pancreatic adenocarcinoma cells. CD82 directly binds to TIMP-1 (zeige TIMP1 Proteine) N-terminal region through its large extracellular loop and co-localizes with TIMP-1 (zeige TIMP1 Proteine).
the results suggest that CD82 suppresses epithelial-to-mesenchymal transition in prostate cancer cells adhered to the fibronectin (zeige FN1 Proteine) matrix by repressing adhesion signaling through lateral interactions with the associated alpha3beta1 and alpha5beta1 integrins, leading to reduced cell migration and invasive capacities.
Overexpression of LAMC2 (zeige LAMC2 Proteine) and knockdown of CD82 markedly promoted GC cell invasion and activated EGFR (zeige EGFR Proteine)/ERK1/2-MMP7 (zeige MMP7 Proteine) signaling via upregulation of the expression of phosphorylated (p)-EGFR (zeige EGFR Proteine), p-ERK1/2 and MMP7 (zeige MMP7 Proteine).
Authors showed that miR (zeige MLXIP Proteine)-K6-5p directly targeted the coding sequence of CD82 molecule (CD82), a metastasis suppressor.
a sub-population of DeltaNp63 and CD82-positive cells, whose disruption significantly perturbs the development of prostate metastatic tumor growth.
These findings uncovered a hitherto unappreciated function of CD82 in severing the linkage between U2AF2 (zeige U2AF59 Proteine)-mediated CD44 (zeige CD44 Proteine) alternative splicing and cancer aggressiveness, with potential prognostic and therapeutic implications in melanoma
a mechanism where the membrane organization of CD82, through specific posttranslational modifications, regulates N-cadherin (zeige CDH2 Proteine) clustering and membrane density, which impacts the in vivo trafficking of AML (zeige RUNX1 Proteine) cells.
Methylation of CpG islands within the KAI1 promoter region was observed in the low KAI1-expressing prostate cancer cells.
CD82 function may be important for muscle stem cell function in muscular disorders.
The overexpression of KAI1/CD82 inhibited the proliferation and invasion of OSCC-15 cells.
This metastasis suppressor gene product is a membrane glycoprotein that is a member of the transmembrane 4 superfamily. Expression of this gene has been shown to be downregulated in tumor progression of human cancers and can be activated by p53 through a consensus binding sequence in the promoter. Its expression and that of p53 are strongly correlated, and the loss of expression of these two proteins is associated with poor survival for prostate cancer patients. Two alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
, inducible membrane protein R2
, kangai 1 (suppression of tumorigenicity 6, prostate)
, metastasis suppressor Kangai-1 homolog
, CD82 antigen
, kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4))
, metastasis suppressor Kangai-1
, CD82 antigen (R2 leukocyte antigen antigen detected by monoclonal and antibody IA4))
, CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4))
, Kangai 1 (suppression of tumerigenicity 6 prostate) CD82 antigen
, Kangai 1 (suppression of tumorigenicity 6, prostate; CD82 antigen (R2 leukocyte antigen, antigen detected by monoclonal and antibody IA4))
, kangai 1 (suppression of tumorigenicity 6), prostate